Reference
1. Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J,
et al. J-Wave syndromes expert consensus conference report: Emerging
concepts and gaps in knowledge. Heart Rhythm. 2016;13(10):e295-324.
2. Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R.
Present Status of Brugada Syndrome: JACC State-of-the-Art Review. J Am
Coll Cardiol. 2018;72(9):1046-59.
3. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, et
al. Long-term prognosis of patients diagnosed with Brugada syndrome:
Results from the FINGER Brugada Syndrome Registry. Circulation.
2010;121(5):635-43.
4. Vutthikraivit W, Rattanawong P, Putthapiban P, Sukhumthammarat W,
Vathesatogkit P, Ngarmukos T, et al. Worldwide Prevalence of Brugada
Syndrome: A Systematic Review and Meta-Analysis. Acta Cardiol Sin.
2018;34(3):267-77.
5. Rattanawong P, Ngarmukos T, Chung EH, Vutthikraivit W, Putthapiban P,
Sukhumthammarat W, et al. Prevalence of Brugada ECG Pattern in Thailand
From a Population-Based Cohort Study. J Am Coll Cardiol.
2017;69(10):1355-6.
6. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al.
HRS/EHRA/APHRS expert consensus statement on the diagnosis and
management of patients with inherited primary arrhythmia syndromes:
document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA,
PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932-63.
7. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the
assessment of the quality of nonrandomized studies in meta-analyses. Eur
J Epidemiol. 2010;25(9):603-5.
8. Kuriachan VP, Sumner GL, Mitchell LB. Sudden cardiac death. Curr
Probl Cardiol. 2015;40(4):133-200.
9. Freeman MF, Tukey JW. Transformations Related to the Angular and the
Square Root. Ann Math Statist. 1950;21(4):607-11.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control
Clin Trials. 1986;7(3):177-88.
11. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of
event outcome in the framework of the generalized linear mixed model
with applications in sparse data. Stat Med. 2010;29(29):3046-67.
12. Debray TPA, Moons KGM, Riley RD. Detecting small-study effects and
funnel plot asymmetry in meta-analysis of survival data: A comparison of
new and existing tests. Research synthesis methods. 2018;9(1):41-50.
13. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of
between-study heterogeneity in meta-analysis: proposed metrics and
empirical evaluation. Int J Epidemiol. 2008;37(5):1148-57.
14. Andorin A, Behr ER, Denjoy I, Crotti L, Dagradi F, Jesel L, et al.
Impact of clinical and genetic findings on the management of young
patients with Brugada syndrome. Heart Rhythm. 2016;13(6):1274-82.
15. Benito B, Sarkozy A, Mont L, Henkens S, Berruezo A, Tamborero D, et
al. Gender differences in clinical manifestations of Brugada syndrome. J
Am Coll Cardiol. 2008;52(19):1567-73.
16. Chinushi M, Komura S, Izumi D, Furushima H, Tanabe Y, Washizuka T,
et al. Incidence and initial characteristics of pilsicainide-induced
ventricular arrhythmias in patients with Brugada syndrome. Pacing Clin
Electrophysiol. 2007;30(5):662-71.
17. Delise P, Allocca G, Marras E, Giustetto C, Gaita F, Sciarra L, et
al. Risk stratification in individuals with the Brugada type 1 ECG
pattern without previous cardiac arrest: usefulness of a combined
clinical and electrophysiologic approach. Eur Heart J.
2011;32(2):169-76.
18. Giustetto C, Drago S, Demarchi PG, Dalmasso P, Bianchi F, Masi AS,
et al. Risk stratification of the patients with Brugada type
electrocardiogram: a community-based prospective study. Europace.
2009;11(4):507-13.
19. Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Tolosana JM,
Gomez-Juanatey A, et al. Patients With Brugada Syndrome and Implanted
Cardioverter-Defibrillators: Long-Term Follow-Up. J Am Coll Cardiol.
2017;70(16):1991-2002.
20. Hiraoka M, Takagi M, Yokoyama Y, Sekiguchi Y, Aihara N, Aonuma K, et
al. Prognosis and risk stratification of young adults with Brugada
syndrome. J Electrocardiol. 2013;46(4):279-83.
21. Kamakura S, Ohe T, Nakazawa K, Aizawa Y, Shimizu A, Horie M, et al.
Long-term prognosis of probands with Brugada-pattern ST-elevation in
leads V1-V3. Circ Arrhythm Electrophysiol. 2009;2(5):495-503.
22. Kharazi A, Emkanjoo Z, Alizadeh A, Nikoo MH, Jorat MV, Sadr-Ameli
MA. Mid-term follow-up of patients with Brugada syndrome following a
cardioverter defibrillator implantation: a single center experience.
Indian Pacing Electrophysiol J. 2007;7(1):33-9.
23. Ohkubo K, Watanabe I, Takagi Y, Okumura Y, Ashino S, Kofune M, et
al. Electrocardiographic and electrophysiologic characteristics in
patients with Brugada type electrocardiogram and inducible ventricular
fibrillation: single center experience. Circ J. 2007;71(9):1437-41.
24. Ouali S, Boughzela E, Haggui A, Haouala H, Battikh K, Ben Ameur Y,
et al. Clinical and electrophysiological profile of Brugada syndrome in
the Tunisian population. Pacing Clin Electrophysiol. 2011;34(1):47-53.
25. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG,
Sassone B, et al. Risk stratification in Brugada syndrome: results of
the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE)
registry. J Am Coll Cardiol. 2012;59(1):37-45.
26. Schukro C, Berger T, Stix G, Pezawas T, Kastner J, Hintringer F, et
al. Regional prevalence and clinical benefit of implantable cardioverter
defibrillators in Brugada syndrome. Int J Cardiol. 2010;144(2):191-4.
27. Conte G, Sieira J, Sarkozy A, de Asmundis C, Di Giovanni G,
Chierchia GB, et al. Life-threatening ventricular arrhythmias during
ajmaline challenge in patients with Brugada syndrome: incidence,
clinical features, and prognosis. Heart Rhythm. 2013;10(12):1869-74.
28. Sieira J, Conte G, Ciconte G, Chierchia GB, Casado-Arroyo R,
Baltogiannis G, et al. A score model to predict risk of events in
patients with Brugada Syndrome. Eur Heart J. 2017;38(22):1756-63.
29. Son MK, Byeon K, Park SJ, Kim JS, Nam GB, Choi KJ, et al. Prognosis
after implantation of cardioverter-defibrillators in Korean patients
with Brugada syndrome. Yonsei Med J. 2014;55(1):37-45.
30. Ueoka A, Morita H, Watanabe A, Morimoto Y, Kawada S, Tachibana M, et
al. Prognostic Significance of the Sodium Channel Blocker Test in
Patients With Brugada Syndrome. J Am Heart Assoc. 2018;7(10).
31. Sieira J, Brugada P. Management of Brugada Syndrome 2016: Should All
High Risk Patients Receive an ICD? All High-Risk Patients Should Receive
an Implantable Cardiac Defibrillator. Circulation Arrhythmia and
electrophysiology. 2016;9(11).
32. Casado-Arroyo R, Berne P, Rao JY, Rodriguez-Manero M, Levinstein M,
Conte G, et al. Long-Term Trends in Newly Diagnosed Brugada Syndrome:
Implications for Risk Stratification. Journal of the American College of
Cardiology. 2016;68(6):614-23.
33. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S.
Autonomic and antiarrhythmic drug modulation of ST segment elevation in
patients with Brugada syndrome. J Am Coll Cardiol. 1996;27(5):1061-70.
34. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin
JA, et al. Sodium channel blockers identify risk for sudden death in
patients with ST-segment elevation and right bundle branch block but
structurally normal hearts. Circulation. 2000;101(5):510-5.
35. Cheung CC, Mellor G, Deyell MW, Ensam B, Batchvarov V, Papadakis M,
et al. Comparison of Ajmaline and Procainamide Provocation Tests in the
Diagnosis of Brugada Syndrome. JACC Clinical electrophysiology.
2019;5(4):504-12.
36. Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, et
al. Outcome after implantation of a cardioverter-defibrillator in
patients with Brugada syndrome: a multicenter study-part 2. Circulation.
2013;128(16):1739-47.
37. Dereci A, Yap SC, Schinkel AFL. Meta-Analysis of Clinical Outcome
After Implantable Cardioverter-Defibrillator Implantation in Patients
With Brugada Syndrome. JACC Clin Electrophysiol. 2019;5(2):141-8.